ADC Therapeutics surges on earnings beat, $261M cash runway fuels optimism
Biotech company narrows losses to $6.4M with ZYNLONTA Phase 3 data expected next quarter
ADC Therapeutics shares climbed nearly 3% in premarket trading on Tuesday after the biotechnology company reported fourth-quarter results that crushed analyst expectations and revealed a substantial cash position to fund operations through 2028.
The Swiss-American company, which develops antibody drug conjugates for hematologic malignancies, posted revenue of $22.3 million for the fourth quarter of 2025, comfortably beating the consensus estimate of $16.8 million, according to regulatory filings. Adjusted loss per share came in at 9 cents, significantly better than the 27- to 32-cent loss that analysts had anticipated.
The net loss narrowed dramatically to $6.4 million from $30.7 million in the prior-year quarter, reflecting improving operational efficiency and growing revenue from ZYNLONTA, the company's flagship treatment for relapsed or refractory diffuse large B-cell lymphoma. For the full year 2025, ADC Therapeutics reported net product revenue of $73.6 million, up from $53.4 million in 2024.
Perhaps most importantly for investors, the company ended the quarter with $261.3 million in cash and cash equivalents, a position management says provides runway at least into 2028. This substantial cash balance removes near-term financing concerns and provides ample resources to fund ongoing clinical programs and potential commercial expansion.
The company's most significant near-term catalyst lies in the LOTIS-5 Phase 3 confirmatory trial, which is evaluating ZYNLONTA in combination with rituximab for second-line diffuse large B-cell lymphoma. Topline data from that trial are expected in the second quarter of 2026, with full results anticipated by year-end, according to clinical trial records. A successful outcome could lead to regulatory submission in the first half of 2026 and potential approval by mid-2027.
Chief Executive Officer Ameet Mallik has emphasized the strategic importance of the LOTIS-5 program, noting that ZYNLONTA's strong single-agent activity and manageable safety profile make it an "ideal combination partner." Analysts estimate that approval in the second-line setting could generate $200 million to $300 million in peak annual sales, according to company investor presentations.
The earnings beat and strong balance sheet have reinforced positive sentiment among Wall Street analysts. ADC Therapeutics currently carries a consensus rating of "Strong Buy" with six analysts rating the stock a Buy and none recommending Hold or Sell, according to MarketBeat data. The average price target of $7.80 represents substantial upside from the current price around $4.23.
RBC Capital maintained an "Outperform" rating with a $5 price target in December 2025, citing strong interim data from the LOTIS-7 Phase Ib trial. Guggenheim has been more bullish, reaffirming a "buy" rating with a $10 target in November 2025. Zacks upgraded the stock to a "Buy" in December, pointing to an upward trend in earnings estimates as a driver for potential share appreciation.
The company faces risks typical of clinical-stage biotechnology companies, including the possibility that the LOTIS-5 trial could fail to meet its primary endpoints or that regulatory authorities could raise safety concerns. ADC Therapeutics also operates in a competitive landscape where larger pharmaceutical companies are developing alternative treatments for B-cell lymphomas.
However, the company's improving financial trajectory, strong cash position, and upcoming clinical data readouts appear to have investors increasingly optimistic about ADC Therapeutics' prospects. The stock, which traded as low as $1.05 in the past year, has recovered significantly and is now approaching its 52-week high of $4.80, reflecting growing confidence in the ZYNLONTA platform's commercial potential.